[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Menstrual Blood Sequencing Effective for HPV Screening Menstrual Blood Sequencing Effective for HPV Screening
Screening for human papillomavirus in high-risk individuals may be done effectively and noninvasively using menstrual blood testing with target-capture sequencing, a clinical study suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 26, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news
Cancer breakthrough: New blood test may detect cancer earlier and more accurately
THE HUMAN papillomavirus is a group of STDs that can produce cancer in several areas of the body. The most common type of cancer is in the head and neck, and a new blood test may make catching it easier. Symptoms of head and neck cancer can include a sore threat, change in voice and pain in the ears. (Source: Daily Express - Health)
Source: Daily Express - Health - December 8, 2021 Category: Consumer Health News Source Type: news
NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Fall 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
NIDCR News
5 Q&As About “Oral Health in America: Advances and Challenges”
NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over the past two decad...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news
American Society for Colposcopy and Cervical Pathology discusses updated American Cancer Society guidelines on cervical cancer screening
(Wolters Kluwer Health) Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening - emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news
To Beat Covid, Beat HIV, & Beat Inequality, Find the Money
A woman is vaccinated against COVID-19 in the indigenous community of Concordia, Colombia. Meanwhile, UN Secretary-General Antonio Guterres repeated his call for the G20 to establish a Task Force “able to deal with the pharmaceutical companies and other key stakeholders”, which would address equitable vaccine distribution through the COVAX global initiative. Credit: WHO/Nadege MazarsBy Winnie ByanyimaGENEVA, May 27 2021 (IPS) In this time of intersecting crises – the Covid crisis, the HIV crisis, the inequality crisis, and more – progress on all these crises is being blocked by another crisis: finance.
Right now, ...
Source: IPS Inter Press Service - Health - May 27, 2021 Category: International Medicine & Public Health Authors: Winnie Byanyima Tags: Aid Development & Aid Featured Global Headlines Health Human Rights Humanitarian Emergencies Population Poverty & SDGs TerraViva United Nations Source Type: news
NHS gives women Human Papillomavirus Virus (HPV) home testing kits to cut cancer deaths
More than 31,000 women will be offered kits to carry out smear tests in the privacy and convenience of their own homes in a trial. (Source: NHS Networks)
Source: NHS Networks - February 24, 2021 Category: UK Health Source Type: news
We All Deserve Protection From Covid-19
Credit: United NationsBy Adaora OkoliNEW ORLEANS, US, Dec 11 2020 (IPS) When I contracted Ebola virus disease in August 2014 while working as a medical doctor in a well-known private hospital in Lagos, Nigeria, I was denied access to a potential cure.
For 15 days, I battled for my life in a debilitated isolation ward, not knowing if I would survive. But American aid workers who contracted Ebola were administered Zmapp, a monoclonal antibody treatment, which reduces the relative risk of death from Ebola by 40% as well as shorten the duration of stay in the Ebola treatment units. They survived.
We were told that Zmapp was e...
Source: IPS Inter Press Service - Health - December 11, 2020 Category: International Medicine & Public Health Authors: Adaora Okoli Tags: Headlines Health TerraViva United Nations Source Type: news
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-throughput co...
Source: Roche Media News - September 16, 2020 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec®PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtecPLUS Cytology to triage positive results from the cobas ® HPV Test run on the fully integrated, automated and high-throughput co...
Source: Roche Investor Update - September 16, 2020 Category: Pharmaceuticals Source Type: news
HPV Test Is Preferred Method for Cervical Cancer Screening: ACS HPV Test Is Preferred Method for Cervical Cancer Screening: ACS
New guidelines recommend human papillomavirus (HPV) testing as the preferred screening method, but cotesting and cytology alone are still acceptable options.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 4, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
American Cancer Society now recommends cervical cancer screening start at 25, not 21
Individuals with a cervix are now recommended to start cervical cancers screening at 25 and continue through age 65, with the primary human papillomavirus (HPV) testing every five years as the preferred method of testing, according to a new guideline released Thursday by the American Cancer Society. (Source: CNN.com - Health)
Source: CNN.com - Health - July 31, 2020 Category: Consumer Health News Source Type: news
American Cancer Society Recommends HPV Test
The new guideline calls for an initial cervix screening at age 25, followed by the human papillomavirus (HPV) test every five years, continuing through age 65, the guideline says. (Source: WebMD Health)
Source: WebMD Health - July 30, 2020 Category: Consumer Health News Source Type: news
BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities
BD Onclarity HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45
FRANKLIN LAKES, N.J., July 22, 2020 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX... Diagnostics, Oncology, FDA BD , Onclarity, HPV Assay, human papillomavirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 22, 2020 Category: Pharmaceuticals Source Type: news
